LA
JOLLA, Calif., Feb. 19,
2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica"
or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium (CRAC) channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced a plenary presentation at the 30th
International Acute Kidney Injury and Continuous Renal Replacement
Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San
Diego, CA.
Details for the presentation are as follows:
Presentation Title: The Role of ORAI-1 in AKI
Presenter: Sudarshan Hebbar, M.D., Chief Medical
Officer of CalciMedica
Session Title: Plenary 2: Bench to Bedside: Translating
Discoveries to Clinical Care
Session Date and Time: Monday,
March 3, 10:35-10:55 a.m.
PT
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product
candidate Auxora™ has demonstrated positive and consistent
clinical results in multiple completed efficacy clinical trials.
CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in
patients with acute pancreatitis (AP) and accompanying systemic
inflammatory response syndrome (SIRS). The Company has also
completed a Phase 2 trial (called CARDEA – NCT04345614) in
patients with COVID pneumonia. The Company is currently conducting
a Phase 2 trial (called KOURAGE – NCT06374797) in patients
with acute kidney injury (AKI) with associated acute hypoxemic
respiratory failure (AHRF) and continuing to support the ongoing
Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric
patients with asparaginase-induced pancreatic toxicity (AIPT).
CalciMedica was founded by scientists from Torrey Pines
Therapeutics and the Harvard CBR Institute for Biomedical Research,
and is headquartered in La Jolla,
CA. For more information, please visit
www.calcimedica.com.
Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-plenary-presentation-at-the-30th-international-aki--crrt-conference-302379681.html
SOURCE CalciMedica, Inc.